Stephan Stilgenbauer

Apr 27, 2024 | nature.com | Luca Fischer |Linmiao Jiang |Stephan Stilgenbauer |Ullrich Graeven |Jochen Greiner |Eric Durot | +3 more

AbstractThe therapy of relapsed or refractory (r/r) mantle cell lymphoma (MCL) patients remains a major clinical challenge to date. We conducted a randomized, open-label, parallel-group phase-III trial hypothesizing superior efficacy of rituximab, high-dose cytarabine and dexamethasone with bortezomib (R-HAD + B) versus without (R-HAD) in r/r MCL ineligible for or relapsed after autologous stem cell transplant (ASCT).

Oct 23, 2023 | nature.com | Othman Al-Sawaf |Christian Pallasch |Martin Peifer |Stephan Stilgenbauer |Michael Hallek

Correction to: Nature Communications https://doi.org/10.1038/s41467-023-37648-w, published online 18 April 2023The original version of this article contained an error in the spelling of the author ‘Joseph N. Paulson’, which was incorrectly given as ‘Joe Paulson’. The original version of this article contained an error in Figure 1d, in which the y axis was labeled ‘Cum Progression-free Survival’ rather than ‘Cum Survival’.

Oct 23, 2023 | nature.com | Othman Al-Sawaf |Christian Pallasch |Martin Peifer |Stephan Stilgenbauer |Michael Hallek

Correction to: Nature Communications https://doi.org/10.1038/s41467-023-37648-w, published online 18 April 2023The original version of this article contained an error in the spelling of the author ‘Joseph N. Paulson’, which was incorrectly given as ‘Joe Paulson’. The original version of this article contained an error in Figure 1d, in which the y axis was labeled ‘Cum Progression-free Survival’ rather than ‘Cum Survival’.